PITTSBURGH, PA and WOODBURY, MN / ACCESSWIRE / July 31, 2023 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ ...
Viatris and Kindeva Drug Delivery announced that Mylan, a Viatris subsidiary, has received the Food and Drug Administration's green light for Breyna, which is the first generic of AstraZeneca’s ...
Viatris Inc. VTRS announced that the company and partner Kindeva Drug Delivery L.P. have won a court decision that invalidates AstraZeneca's AZN patent for Symbicort. The U.S. District Court for the ...
Viatris’ generic Breyna could reach a large number of patients. The generic could generate $150 million in annual revenue for the company. Viatris’ shares today sell at an attractive valuation.
PITTSBURGH, PA and WOODBURY, MN / ACCESSWIRE / July 31, 2023 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna (budesonide ...
Viatris and Kindeva Drug Delivery announced that they have won a significant court decision in which the U.S. District Court for the Northern District of West Virginia found that AstraZeneca's ...
PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results